Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 14
Review
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 26,234 | Dovepress* | 14,010+ | 2,411 | 16,421 | |
| PubMed Central* | 12,224 | 2,091 | 14,315 | ||
| Totals | 26,234 | 4,502 | 30,736 | ||
| *Since 20 July 2018 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 3 | 0 | 0 | 0 | 0 | 3 |
View citations on PubMed and Google Scholar